|MDACC Study No:||2012-0062 (clinicaltrials.gov NCT No: NCT01546038)|
|Title:||A Phase 1B/2 Study to Evaluate the Safety and Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-C or Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|
|Principal Investigator:||Jorge Cortes|
|Treatment Agent:||Cytarabine; Daunorubicin; PF-04449913|
|Study Description:||The goal of the screening part of this clinical research study is find the |
group that you will be assigned to in the main study.
The goal of the main part of the study is to learn the highest tolerable dose
of PF-04449913 that can be given with chemotherapy to patients with AML or
high-risk MDS and to learn if the study drug can help to control the disease.
PF-04449913 is designed to stop the growth of certain cancer stem cells that
may allow cancer to grow.